Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes
Open Access
- 11 April 2014
- journal article
- research article
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 14 (1) , 35
Abstract
Insulin aspart (IAsp) and its biphasic preparations BIAsp50 and BIAsp70 (containing 50% and 70% IAsp, respectively) have distinct glucose-lowering properties as compared to human insulin (HI). We investigated whether this affected the circulating IGF-system which depends on the hepatic insulin exposure. In a randomized, four-period crossover study, 19 patients with type 1 diabetes received identical doses (0.2 U/kg sc) of IAsp, BIAsp70, BIAsp50 and HI together with a standardized meal. Serum total IGF-I and IGFBP-1 to -3 were measured by immunoassays for nine hours post-prandially. Bioactive IGF was determined by an in-house, cell-based IGF-I receptor kinase activation (KIRA) assay. Despite marked differences in peripheral insulin concentrations and plasma glucose, the four insulin preparations resulted in parallel decreases in IGFBP-1 levels during the first 3 hours, and parallel increases during the last part of the study (3–9 hours). Thus, only minor significances were seen. Insulin aspart and human insulin resulted in a lower area under the curve (AUC) during the first 3 hours as compared to BIAsp70 (p = 0.009), and overall, human insulin resulted in a lower IGFBP-1 AUC than BIAsp70 (p = 0.025). Nevertheless, responses and AUCs of bioactive IGF were similar for all four insulin preparations. Changes in levels of bioactive IGF were inversely correlated to those of IGFBP-1, increasing during the first 3 hours, whereafter levels declined (-0.83 ≤ r ≤ -0.30; all p-values <0.05). Total IGF-I and IGFBP-3 remained stable during the 9 hours, whereas IGFBP-2 changed opposite of IGFBP-1, increasing after 3–4 hours whereafter levels gradually declined. The four insulin preparations resulted in similar profiles and AUCs of total IGF-I, IGFBP-2 and IGFBP-3. Despite distinct glucose-lowering properties, the tested insulin preparations had similar effects on IGF-I concentration and IGF bioactivity, IGFBP-2 and IGFBP-3 as compared to HI; only small differences in IGFBP-1 were seen and they did not affect bioactive IGF. Thus, insulin aspart containing preparation behaves as HI in regards to the circulating IGF-system. However, bioactive IGF appeared to be more sensitive to insulin exposure than total IGF-I. The physiological significance of this finding remains to be determined. NCT00888732Keywords
This publication has 31 references indexed in Scilit:
- Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancerNature Reviews Drug Discovery, 2007
- Mechanisms of Disease: metabolic effects of growth hormone and insulin-like growth factor 1Nature Clinical Practice Endocrinology & Metabolism, 2007
- The Growth Hormone Hypothesis - 2005 RevisionHormone and Metabolic Research, 2005
- Residual β-Cell Function More than Glycemic Control Determines Abnormalities of the Insulin-Like Growth Factor System in Type 1 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2004
- The physiological and pathophysiological roles of the GH/IGF-axis in the kidney: Lessons from experimental rodent modelsGrowth Hormone & IGF Research, 2004
- Insulin AspartDrugs, 2004
- The role of the growth hormone–insulin‐like growth factor axis in glucose homeostasisDiabetic Medicine, 2003
- Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type 1 diabetesEuropean Journal of Endocrinology, 2000
- Alterations in the Growth Hormone-Insulin-Like Growth Factor Axis in Insulin Dependent Diabetes MellitusHormone and Metabolic Research, 1999
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993